Monopar Therapeutics 8-K, filed Feb 9, 2021
Monopar Therapeutics (MNPR)
8-K
2021-02-09
For: 2021-02-09
View Original
Added on
April 10, 2026
About this 8-K
Monopar Therapeutics filed this 8-K on February 9, 2021.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): February 9, 2021
MONOPAR
THERAPEUTICS INC.
(Exact name of registrant as specified in
its charter)
|
Delaware
|
|
001-39070
|
|
32-0463781
|
|
(State or other
jurisdiction of incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
1000
Skokie Blvd., Suite 350, Wilmette,
IL 60091
|
|
60091
|
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
(847)
388-0349
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the
Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
Common
Stock, $0.001 par value
|
|
MNPR
|
|
The
Nasdaq Stock Market LLC
(Nasdaq Capital Market)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§ 240.12b-2 of this chapter).
Emerging growth
company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☒
Item 7.01 Regulation FD Disclosure
On February 9,
2021, Monopar Therapeutics Inc. (“Monopar”) issued a
press release announcing the
issuance of a patent covering composition of matter for MNPR-101 in
Canada, adding to its existing protection in key markets around the
world including the US, Europe and Japan.
The
press release is furnished as Exhibit 99.1 to this report and
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
|
Exhibit No.
|
Description
|
|
99.1
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
Monopar
Therapeutics Inc.
|
|
|
|
|
|
|
|
|
Date: February 9,
2021
|
By:
|
/s/
Kim
R. Tsuchimoto
|
|
|
|
|
Name: Kim
R. Tsuchimoto
|
|
|
|
|
Title:
Chief
Financial Officer, Secretary and Treasurer
|
|
Monopar Announces Issuance of Patent
Covering Composition of Matter for MNPR-101 in
Canada
WILMETTE, Ill., February 9, 2021 – Monopar
Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
biopharmaceutical company primarily focused on developing
proprietary therapeutics designed to extend life and improve the
quality of life for cancer patients, today announced the issuance
of a patent covering composition of matter for MNPR-101 in Canada,
adding to its existing protection in key markets around the world
including the US, Europe and Japan.
“This
is an important advancement in our efforts to broaden our global
patent estate for MNPR-101,” said Chandler Robinson, MD,
Chief Executive Officer of Monopar. “MNPR-101 is a novel,
first-in-class humanized monoclonal antibody to the urokinase
Plasminogen Activator Receptor (uPAR). uPAR is a well credentialed
target that appears to be overexpressed in certain aberrantly
activated cells, but does not appear much, if at all, in healthy
tissue.”
In June
2020, Monopar entered into a collaboration with NorthStar Medical
Radioisotopes, LLC to utilize MNPR-101 to create a
radio-immuno-therapeutic (RIT) to potentially treat severe COVID-19
by targeting and eradicating the aberrantly activated immune cells
causing cytokine storm. uPAR targeting by MNPR-101 has wide
potential in treating other diseases as well, including cancers, as
uPAR is over-expressed in multiple cancer types such as pancreatic
and ovarian.
“We
are excited about the approval of this composition of matter patent
in Canada as it further enables us to explore the potential of
MNPR-101 on a global scale,” said Andrew Mazar, PhD, Chief
Scientific Officer of Monopar.
About Monopar Therapeutics Inc.
Monopar
Therapeutics is a clinical-stage biopharmaceutical
company primarily focused on developing proprietary
therapeutics designed to extend life or improve the quality of life
for cancer patients. Monopar's pipeline consists of Validive®
for the prevention of chemoradiotherapy-induced severe oral
mucositis in oropharyngeal cancer patients; camsirubicin for the
treatment of advanced soft tissue sarcoma; and a late-stage
preclinical antibody, MNPR-101, for advanced cancers and
severe COVID-19. For more information, visit: www.monopartx.com.
Forward-Looking Statements
Statements
contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
The words “may,” “will,”
“could,” “would,” “should,”
“expect,” “plan,” “anticipate,”
“intend,” “believe,”
“estimate,” “predict,”
“project,” “potential,”
“continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Examples of
these forward-looking statements include statements
concerning: whether Monopar’s composition of matter
patents (including in Canada) provide protection in key markets
around the world; whether
Monopar’s collaboration with NorthStar Medical Radioisotopes,
LLC utilizing MNPR-101 to create a radio-immuno-therapeutic (RIT)
will result in a treatment for severe COVID-19 by targeting and
eradicating the aberrantly activated immune cells causing cytokine
storm; and whether MNPR-101 has wide potential in treating other
diseases including cancers such as pancreatic and ovarian. The
forward-looking statements involve risks and uncertainties
including, but not limited to: Monopar’s composition of
matter patents (including in Canada) not providing protection in
key markets around the world; Monopar and NorthStar are unable to
develop a RIT to treat severe COVID-19; further development of
MNPR-101 does not result in a treatment for cancers; the
requirement for Monopar to raise additional capital to complete
clinical development of MNPR-101 or a RIT, if at all; the potential
for commercialization and uncertainties about levels of demand if
and when a treatment is available for commercialization; and the
significant and general risks and uncertainties surrounding the
research, development, regulatory approval and commercialization of
therapeutics. Actual results may differ materially from
those expressed or implied by such forward-looking statements.
Risks are described more fully in Monopar's filings with the
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Monopar undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made.
Any forward-looking statements contained in this press release
represent Monopar’s views only as of the date hereof and
should not be relied upon as representing its views as of any
subsequent date.
CONTACT:
Monopar Therapeutics Inc.:
Investor
Relations:
Kim R.
Tsuchimoto
Chief
Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates:
@MonoparTx
Monopar
Therapeutics